| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 16.4M | 19.94M | 1.89M |
| Revenue Growth % | - | - | - | - | 0.22% | -0.91% |
| Cost of Goods Sold | 463K | 777K | 0 | 2.51M | 1.76M | 1.81M |
| COGS % of Revenue | - | - | - | 0.15% | 0.09% | 0.96% |
| Gross Profit | -463K | -777K | 0 | 13.89M | 18.18M | 71K |
| Gross Margin % | - | - | - | 0.85% | 0.91% | 0.04% |
| Gross Profit Growth % | - | -0.68% | 1% | - | 0.31% | -1% |
| Operating Expenses | 9.94M | 21.63M | 50.09M | 69.95M | 58.68M | 73.67M |
| OpEx % of Revenue | - | - | - | 4.26% | 2.94% | 39.08% |
| Selling, General & Admin | 3.6M | 5.76M | 14.82M | 21.5M | 18.67M | 19.05M |
| SG&A % of Revenue | - | - | - | 1.31% | 0.94% | 10.1% |
| Research & Development | 6.34M | 16.64M | 35.27M | 53.76M | 41.78M | 56.43M |
| R&D % of Revenue | - | - | - | 3.28% | 2.09% | 29.94% |
| Other Operating Expenses | 0 | -777K | 0 | -5.32M | -1.76M | -1.81M |
| Operating Income | -9.94M | -22.4M | -50.09M | -56.06M | -40.5M | -73.59M |
| Operating Margin % | - | - | - | -3.42% | -2.03% | -39.04% |
| Operating Income Growth % | - | -1.25% | -1.24% | -0.12% | 0.28% | -0.82% |
| EBITDA | -9.47M | -21.63M | -49.87M | -53.55M | -38.74M | -71.78M |
| EBITDA Margin % | - | - | - | -3.26% | -1.94% | -38.08% |
| EBITDA Growth % | - | -1.28% | -1.31% | -0.07% | 0.28% | -0.85% |
| D&A (Non-Cash Add-back) | 463K | 777K | 216K | 2.51M | 1.76M | 1.81M |
| EBIT | -9.88M | -15.04M | -50.09M | -53.81M | -34.23M | -65.86M |
| Net Interest Income | 0 | 101K | 104K | 1.91M | 4.28M | 2.02M |
| Interest Income | 372K | 101K | 104K | 1.91M | 7.42M | 6.67M |
| Interest Expense | 372K | 0 | 0 | 0 | 3.14M | 4.66M |
| Other Income/Expense | -312K | 7.36M | 104K | 2.25M | 3.13M | 3.08M |
| Pretax Income | -10.25M | -15.04M | -49.98M | -53.81M | -37.37M | -70.52M |
| Pretax Margin % | - | - | - | -3.28% | -1.87% | -37.41% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1.07% | 0.99% | 1% | 1% | 1% | 1% |
| Net Income | -10.99M | -14.94M | -49.98M | -53.81M | -37.37M | -70.52M |
| Net Margin % | - | - | - | -3.28% | -1.87% | -37.41% |
| Net Income Growth % | - | -0.36% | -2.35% | -0.08% | 0.31% | -0.89% |
| Net Income (Continuing) | -10.25M | -15.04M | -49.98M | -53.81M | -37.37M | -70.52M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.38 | -0.98 | -10.94 | -1.86 | -1.05 | -1.63 |
| EPS Growth % | - | -1.58% | -10.16% | 0.83% | 0.44% | -0.55% |
| EPS (Basic) | -0.38 | -0.98 | -10.94 | -1.86 | -1.05 | -1.63 |
| Diluted Shares Outstanding | 28.66M | 28.66M | 18.45M | 28.86M | 35.65M | 43.86M |
| Basic Shares Outstanding | 28.66M | 28.66M | 18.45M | 28.86M | 35.65M | 43.33M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 18.06M | 92.91M | 161.07M | 140.2M | 138.37M | 113.07M |
| Cash & Short-Term Investments | 17.9M | 92.57M | 157.53M | 129.31M | 134.34M | 111M |
| Cash Only | 17.9M | 92.57M | 157.53M | 129.31M | 134.34M | 111M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 6.93M | 1.35M | 0 |
| Days Sales Outstanding | - | - | - | 154.18 | 24.71 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 75K | 0 | 100K | 3.96M | 2.68M | 2.07M |
| Total Non-Current Assets | 3.62M | 3.48M | 18.18M | 20.05M | 36.46M | 13.86M |
| Property, Plant & Equipment | 3.41M | 3.12M | 16.32M | 17.45M | 14.85M | 12.32M |
| Fixed Asset Turnover | - | - | - | 0.94x | 1.34x | 0.15x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 1.21M | 21.02M | 1.22M |
| Other Non-Current Assets | 208K | 362K | 1.86M | 1.38M | 594K | 320K |
| Total Assets | 21.68M | 96.4M | 179.25M | 160.25M | 174.83M | 126.93M |
| Asset Turnover | - | - | - | 0.10x | 0.11x | 0.01x |
| Asset Growth % | - | 3.45% | 0.86% | -0.11% | 0.09% | -0.27% |
| Total Current Liabilities | 2.04M | 5.28M | 11.87M | 23.99M | 19.38M | 15.18M |
| Accounts Payable | 633K | 1.02M | 2.04M | 1.22M | 1.34M | 3.04M |
| Days Payables Outstanding | 499.02 | 479.62 | - | 177.56 | 276.44 | 610.68 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 6.67M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1000K | 907K | 0 |
| Other Current Liabilities | 0 | 94K | 163K | 11.02M | 3.63M | 10.59M |
| Current Ratio | 8.84x | 17.58x | 13.56x | 5.84x | 7.14x | 7.45x |
| Quick Ratio | 8.84x | 17.58x | 13.56x | 5.84x | 7.14x | 7.45x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 9.87M | 1.9M | 14.59M | 13.92M | 44.08M | 38.36M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 32.66M | 26.09M |
| Capital Lease Obligations | 2.54M | 1.86M | 14.59M | 12.6M | 10.99M | 9.44M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.32M | 31K | 0 | 1.32M | 433K | 2.83M |
| Total Liabilities | 11.91M | 7.18M | 26.46M | 37.91M | 63.46M | 53.54M |
| Total Debt | 3.14M | 2.54M | 15.66M | 14.68M | 51.92M | 37.09M |
| Net Debt | -14.76M | -90.03M | -141.87M | -114.63M | -82.42M | -73.91M |
| Debt / Equity | 0.32x | 0.03x | 0.10x | 0.12x | 0.47x | 0.51x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -26.71x | - | - | - | -12.90x | -15.81x |
| Total Equity | 9.77M | 89.22M | 152.79M | 122.34M | 111.37M | 73.39M |
| Equity Growth % | - | 8.13% | 0.71% | -0.2% | -0.09% | -0.34% |
| Book Value per Share | 0.34 | 3.11 | 8.28 | 4.24 | 3.12 | 1.67 |
| Total Shareholders' Equity | 9.77M | 89.22M | 152.79M | 122.34M | 111.37M | 73.39M |
| Common Stock | 2K | 2K | 2K | 3K | 4K | 5K |
| Retained Earnings | -24.41M | -51.87M | -252.9M | -306.7M | -344.07M | -414.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -9.54M | -18.62M | -42.88M | -40.6M | -32.61M | -56.19M |
| Operating CF Margin % | - | - | - | -2.48% | -1.64% | -29.81% |
| Operating CF Growth % | - | -0.95% | -1.3% | 0.05% | 0.2% | -0.72% |
| Net Income | -10.25M | -15.04M | -49.98M | -53.81M | -37.37M | -70.52M |
| Depreciation & Amortization | 25K | 150K | 216K | 1.1M | 1.76M | 1.81M |
| Stock-Based Compensation | 559K | 632K | 4.09M | 7.4M | 8.01M | 8.83M |
| Deferred Taxes | -117K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 950K | -6.29M | 519K | 2.17M | 878K | 1.16M |
| Working Capital Changes | -711K | 1.92M | 2.28M | 2.54M | -5.89M | 2.53M |
| Change in Receivables | 0 | 0 | 0 | -6.93M | 5.58M | 1.35M |
| Change in Inventory | 0 | 0 | 0 | 6.93M | 0 | 0 |
| Change in Payables | 116K | 0 | 1.01M | -883K | -4.33M | 3.46M |
| Cash from Investing | -266K | -560K | -498K | -3.61M | -769K | -254K |
| Capital Expenditures | -266K | -560K | -498K | -3.61M | -769K | -254K |
| CapEx % of Revenue | - | - | - | 0.22% | 0.04% | 0.13% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 21.91M | 93.86M | 109.43M | 15.91M | 58.43M | 13.08M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | -193K | 93.86M | -2.17M | 166K | 100K | -496K |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -9.81M | -19.18M | -43.37M | -44.21M | -33.38M | -56.44M |
| FCF Margin % | - | - | - | -2.7% | -1.67% | -29.94% |
| FCF Growth % | - | -0.96% | -1.26% | -0.02% | 0.24% | -0.69% |
| FCF per Share | -0.34 | -0.67 | -2.35 | -1.53 | -0.94 | -1.29 |
| FCF Conversion (FCF/Net Income) | 0.87x | 1.25x | 0.86x | 0.75x | 0.87x | 0.80x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -112.5% | -30.18% | -41.31% | -39.12% | -31.98% | -76.33% |
| Return on Invested Capital (ROIC) | - | - | -743.35% | -451.51% | -165.72% | -388.21% |
| Gross Margin | - | - | - | 84.7% | 91.15% | 3.77% |
| Net Margin | - | - | - | -328.09% | -187.37% | -3740.85% |
| Debt / Equity | 0.32x | 0.03x | 0.10x | 0.12x | 0.47x | 0.51x |
| Interest Coverage | -26.71x | - | - | - | -12.90x | -15.81x |
| FCF Conversion | 0.87x | 1.25x | 0.86x | 0.75x | 0.87x | 0.80x |
| Revenue Growth | - | - | - | - | 21.6% | -90.55% |
| 2024 | |
|---|---|
| Reportable | 1.89M |
| Reportable Growth | - |
Werewolf Therapeutics, Inc. (HOWL) reported $1.9M in revenue for fiscal year 2024.
Werewolf Therapeutics, Inc. (HOWL) saw revenue decline by 90.5% over the past year.
Werewolf Therapeutics, Inc. (HOWL) reported a net loss of $72.8M for fiscal year 2024.
Werewolf Therapeutics, Inc. (HOWL) has a return on equity (ROE) of -76.3%. Negative ROE indicates the company is unprofitable.
Werewolf Therapeutics, Inc. (HOWL) had negative free cash flow of $63.6M in fiscal year 2024, likely due to heavy capital investments.